LDS/Medical Tests/c-KIT Mutation Analysis, Blood, Bone Marrow

c-KIT Mutation Analysis, Blood, Bone Marrow

c-KIT is a proto-oncogene that encodes a Type-III transmembrane tyrosine kinase receptor. c-KIT and its ligand stem cell factor play a key role in survival, proliferation, differentiation, and functional activation of hematopoietic progenitor cells. c-Kit is expressed at high levels in hematopoietic stem cells, mast cells, melanocytic cells, germ cells, and the interstitial cells of Cajal. c-KIT mutations are reported in nearly all systemic mastocytosis cases with the most common being Asp816Val c-KIT mutation, 20% – 40% of core-binding factor (CBF) acute myeloid leukemia (AML) cases (those with t(8;21)(q22;q22) and inv(16)(p13q22) genomic rearrangements), and approximately 20% of assayed high-grade myelodysplastic syndrome (MDS) and MDS-derived AML patients.

A c-KIT mutation in AML confers increased risk of relapse and decreased overall survival. c-KIT mutation is also seen in 80 - 85% of gastrointestinal stromal tumors (GIST, GI Stromal Tumor). c-Kit (CD117) antigen is usually detected by IHC (immunohistochemistry). Identification of this mutation can lead to improved patient care. For example, a tyrosine kinase inhibitor, such as imatinib, has been evaluated to treat GI stromal tumors, systemic mastocytosis and c-KIT-positive AML and MDS. The Asp816Val mutation in systemic mastocytosis is relevant to patient therapy because it confers resistance to the drug imatinib. The treatment was found effective as a single reagent or combination therapy in those without this mutation.

  • As an aid in diagnosis of mastocytosis
  • As an aid in evaluation of acute myeloid leukemia
  • As an aid in evaluation of myelodysplastic syndrome
  • As an aid in diagnosis of gastrointestinal stromal tumors (GIST)
  • As an aid in diagnosis of melanoma
  • Disease management and therapy monitoring

Increased in (positive for mutation):

  • Systemic mastocytosis
  • Acute myeloid leukemia
  • Myelodysplastic syndrome
  • Myelodysplastic syndrome derived AML
  • Gastrointestinal stromal tumors
  • Myeloproliferative disorders
  • Melanoma
  • Lymphoma
  • Seminoma

 

Negative (Mutation not detected)
 

 

  • Polymerase Chain Reaction (PCR) and ASPE
  • High Performance Liquid Chromatography (HPLC)
  • DNA Sequence Analysis

Whole blood, bone marrow.

CBC with Manual Differential, FLT3 Mutation, Leukemia Profile by Flow Cytometry, Cytogenetics (Chromosomal Analysis), other Acute Myeloid Leukemia Translocations and Immunophenotype Markers.
Approximately 1 week.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login